Manufactured under ISO 22000 and NSF 455-2 GMP cleanroom protocols. Formulated with verified target bioactive molecules to solve dissolution, stability, and digestive bioavailability challenges.
Supercritical CO2 extract standardized for 85–95% total fatty acids and phytosterols, combined with microencapsulated lycopene to optimize prostate cell support.
Fully chelated multi-pathway matrix featuring Glycinate, Malate, and Taurate. Engineered for high elemental yield with minimal gastrointestinal transit sensitivity.
Gastric-acid-resistant DRCaps encasing 10 freeze-dried resilient strains supplemented with fructooligosaccharides, ensuring viable CFU delivery to the lower colon.
Chromatographically authenticated alpine Rhodiola concentrate guaranteed to deliver a 3:1 ratio of rosavins to salidroside to counter cortisol fluctuations and mental fatigue.
Synergistic parasympathetic system activator combining enantiopure fermentation-derived Suntheanine-grade L-Theanine with microbial GABA and calming elemental magnesium.
Pharmaceutical-grade cholecalciferol stabilized in natural plant lipid carriers to resist oxidation and maximize systemic absorption in bone and cellular immune response.
Chamomile-derived isolated apigenin (98%) paired with bisglycinate chelate and amino acids to trigger GABA-A receptors for deeper REM sleep architectures.
Complete skeletal homeostasis complex utilizing microencapsulated Menaquinone MK-7 (Vitamin K2) to ensure calcium carboxylates directly into bone tissue rather than vascular walls.
The botanical and functional ingredients sector has moved permanently beyond arbitrary bulk powders. Procurement teams now require precision chromatographic fingerprinting, targeted molecular weight spectrums, and auditable sustainability from soil to shelf.
The global regulatory apparatus has made crude extraction ratios (e.g., 10:1 or 20:1) obsolete. Modern B2B procurement demands HPLC, LC-MS, and GC-MS verified markers. Brand equity depends on batch-to-batch chemical stability that guarantees identical active payloads across production runs.
Import rejections across the US FDA and European EFSA are dominated by cross-contamination. Sourcing concentrates requires non-negotiable verification of USP <561> multi-pesticide screens, heavy metals (Pb, As, Cd, Hg) below 0.1 ppm via ICP-MS, and strict controls on polycyclic aromatic hydrocarbons (PAH4).
Organic non-polar solvents like hexanes and chlorinated carbons are systematically being prohibited. Sourcing focuses on Supercritical Fluid Extraction (SFE-CO2), subcritical continuous countercurrent water extraction, and solvent-free enzymatic processing that leaves zero residual volatile petrochemical compounds.
| Evaluation Parameter | Conventional Commodity Extractors | ESNO Biotech Precision Manufacturing | Procurement & Commercial Impact |
|---|---|---|---|
| Bioactive Fingerprint | Unverified TLC or UV spectroscopy; generic ratios | Quantitative HPLC, UPLC, GC-MS & NMR confirmation | Prevents commercial adulteration and regulatory recalls |
| Heavy Metals Control | Total heavy metals colorimetric testing (<20 ppm) | Element-specific ICP-MS analysis (Pb, As, Cd, Hg < 0.1 ppm) | Complies with California Proposition 65 & EU 2023/915 |
| Particle Kinetics | Irregular crystalline agglomerates, poor compressibility | Fluidized-bed granulation, microencapsulation & DC grades | Accelerates high-speed encapsulator output by up to 45% |
| Microbiological Integrity | Chemical fumigation, ethylene oxide (EtO) residues | High-pressure steam sterilization & irradiation-free cleanrooms | Preserves organic certifications and removes carcinogen hazards |
Phytochemical efficacy has reached an inflection point. As consumers demand fast, clinical results, brand formulators must solve raw material limitations through advanced delivery systems and synthetic biology integration.
Hydrophobic plant compounds like curcumin, apigenin, and silymarin face poor intestinal absorption. Encapsulating concentrates within phospholipid bilayers multiplies clinical bioavailability by 6x to 12x.
Eliminate supply adulteration through genetic authentication. Each production run of botanical concentrate includes genomic DNA barcoding verified back to wildcrafted or cultivated farms.
Utilizing microbial enzyme cascades to convert high-abundance plant ginsenosides or flavonoids into rare, biologically active aglycones (e.g., Rare Ginsenoside Rh2/Rg3 and Urolithin A).
Low-temperature nitrogen-blanketed atomization protects thermolabile terpenes and polyphenols against thermal breakdown, delivering uniform flowability for automated encapsulation.
Founded in 2006 in Xi'an, the industrial center of botanical extraction in Shaanxi, China, ESNO Biotech delivers end-to-end OEM/ODM manufacturing spanning bulk active extraction to retail-ready blister packs and bottling.
Fully licensed production facilities certified to NSF 455-2 GMP, ISO 22000, and HACCP, with on-site facility and supply audits verified by TÜV Rheinland. Meets both EU Organic and USDA NOP requirements.
Each commercial shipment comes standard with an exhaustive batch Certificate of Analysis (COA), heavy metal profiles, solvent residues, allergen statements, BSE/TSE-free certifications, and finished package design reviews.
Reduce risk with our flexible MOQs starting from 100 to 500 units for select capsule lines, alongside scale capacity for high-volume contract runs across hard capsules, pectin gummies, softgels, and sachet stick packs.
Technical and commercial answers addressing formula viability, lab auditing, and shipping compliances.
Partner directly with Shaanxi ESNO Biotech Co., Ltd. Get detailed Certificates of Analysis, formula stability evaluations, and custom pilot pricing for your private-label supplement product line.